Evexia Lifecare Ltd Plans Major Expansion; To Enter Into Bullion Trading

Vadodara (Gujarat) [India], October 11: BSE listed (524444), Evexia Lifecare Limited has received initial plant layout permission from FDA to setup Active Pharmaceutical Ingredient (API) manufacturing plant of Isometamidium (Isometa) in addition to the current ongoing commercial activity, mainly used for the rare diseases in cattle, buffalo, goat, dogs, etc. Very few companies are manufacturing the said API in India and worldwide. The Company has completed the application process for environment clearance with the concerned government authority and has procured all the required plant and machinery at the Vadodara plant location. Once the Company receives the Environment Clearance (EC) from the concerned Government Authorities, the installation and production work will commence.

Further, the Board of Directors of one of the subsidiary companies, namely Kavit Trading Private Limited, where Evexia holds 70% of the shareholding, has approved the business of direct buying of bullion from the Banks and selling in the market. The said subsidiary company has approached bankers for the opening of Bullion Accounts with them. This new business will boost the revenue of the said subsidiary company and consequently improve the Company’s consolidated financials.

Apart from the ISOMETA API product, Evexia Lifecare Limited is also planning to manufacture intermediate, mainly used for anti-diabetic and heart diseases, at Vadodara based plant location. The Research & Development (R & D) team is at the final stage of five more products that the Company may launch by November 2021.

The Company is at an advanced stage of acquiring Akola (Maharashtra) based existing plant of one of the manufacturers of ISOMETA API, which will increase production capacity and profitability.

The Company’s vision is to enter into formulation by January 2022, which will give a push to the Company’s growth for the long term. The R & D team has already started work for the formulation plant, looking into the opportunity and available market in India and across the globe.

The Company has started its new branch at Hyderabad location to trade pharmaceutical chemicals, and the same will likely contribute Rs. 25-30 Cr turnover per year.

For the above all expansion activities, the Company will manage the funds internally, and the board is not expecting any external borrowings.

Business

Phoenixx Artists: An Application Illuminating the Journey to Stardom in Bollywood and Hollywood curated by Gaurang Doshi and Niti Agarwal

Mumbai (Maharashtra) [India], May 21: A new dawn rises in the world of entertainment as Gaurang Doshi, Bollywood’s acclaimed director and producer, teamed up with Niti Agarwal, the owner of TTF Productions to unveil their magnum opus – ”Phoenixx Artists”. Phoenixx Artists, a subscription-based platform, represents a paradigm shift, offering a celestial pathway for both […]

Read More
Business

Shaping Success: The Dynamic Profiles of India’s Top 10 Businesses

New Delhi [India], May 21: Discover the stories behind India’s most influential companies in this insightful exploration. From innovative startups to established industry leaders, the listicle delves into the strategies, leadership, and market impact that have propelled these firms to the forefront of their sectors. Uncover the secrets of their success and the visionary individuals […]

Read More
Business

Iconic Fusion: Maison De Couture partners majoliX Global

New Delhi [India], May 21: In a unique collaboration poised to relook the landscape of contemporary fashion, “Maison De Couture,” the renowned French luxury fashion house, joins hands with “majoliX Global,” a new age consulting and digital solutions organization dedicated to promoting Indian products, services, and management expertise worldwide. This collaboration heralds an era of […]

Read More